ExThera Medical is developing revolutionary medical devices that address unmet clinical needs in the treatment of bloodstream infections and pathogen-reduction in blood banking.
Bloodstream infections are a global health issue and are increasing in prevalence despite significant efforts to find effective treatments. If not identified and treated early, these infections can cause serious illness, progress to sepsis and lead to permanent organ damage or even death.
ExThera Medical is developing a first-of-its-kind blood filter designed to capture and remove a broad range of bacteria, viruses, toxins and pro-inflammatory cytokines from whole blood. Harmful substances are captured and adsorbed onto the device’s proprietary surface and are thereby removed from the bloodstream without adding anything to the treated blood, which is then returned to the patient’s body with blood cells intact.
The company is immediately focused on therapeutic applications to treat drug-resistant and drug-susceptible bloodstream infections in high-risk patient populations, but also intends to develop a device that prophylactically safeguards banked human blood.
Steven Opal, M.D. (Brown University) editorial in Critical Care highlights the need for non-antibiotic alternatives for treating pan-resistant bloodstream infections, referencing our work with Seraph.
ExThera Medical is sponsoring a prospective, multi-center, non-randomized European trial for the Seraph® Microbind® Affinity Blood Filter (Seraph).